Erratum to: Invest New Drugs
The article First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors, written by S. Fu, H. Hirte, S. Welch, T. T. Ilenchuk, T. Lutes, C. Rice, N. Fields, A. Nemet, D. Dugourd, S. Piha-Paul, V. Subbiah, L. Liu, J. Gong, D. Hong, and J. M. Stewart, was originally published electronically on the publisher’s internet portal (currently SpringerLink) on 01 February 2017 without open access.
With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 05 April 2017 to © The Author(s) 2017 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The online version of the original article can be found at doi: http://dx.doi.org/10.1007/s10637-017-0438-z
About this article
Cite this article
Fu, S., Hirte, H., Welch, S. et al. Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs 35, 397 (2017). https://doi.org/10.1007/s10637-017-0455-y